Literature DB >> 8068600

Apolipoprotein(a) phenotypes predict the risk for carotid atherosclerosis in patients with end-stage renal disease.

F Kronenberg1, H Kathrein, P König, U Neyer, W Sturm, K Lhotta, E Gröchenig, G Utermann, H Dieplinger.   

Abstract

Several studies have demonstrated that atherosclerotic complications are the major cause of morbidity and mortality in hemodialysis patients. High lipoprotein(a) [Lp(a)] plasma concentrations are an independent risk factor for atherosclerosis. Patients with end-stage renal disease (ESRD) have elevated plasma concentrations of Lp(a), which are not explained by size variation at the apolipoprotein(a) [apo(a)] gene locus. The aim of our study was to investigate whether Lp(a) concentrations and/or apo(a) phenotypes are predictive of the degree of atherosclerosis in the extracranial carotid arteries in ESRD patients. Of 167 patients, 108 showed atherosclerotic plaques (65%). Univariate analysis showed that the plaque-affected group was significantly older and had a higher frequency of angina pectoris, previous myocardial infarction, or cerebrovascular accident. Furthermore, this group included significantly more patients with low-molecular-weight apo(a) isoforms (26.9% versus 8.5%, P < .005) and had significantly higher mean Lp(a) plasma concentrations (29.3 +/- 31.0 versus 19.7 +/- 25.7 mg/dL, P < .05). Lp(a) plasma concentration increased significantly with the number of affected arterial sites, from 19.7 mg/dL in patients without plaques to 40.1 mg/dL in patients with seven or eight affected sites. In patients with low-molecular-weight phenotypes, significantly more arterial sites were affected (3.62 versus 2.08, P < .001). Multivariate regression analysis showed that age, angina pectoris, and the apo(a) phenotype were the only significant predictors of the degree of atherosclerosis. We conclude that, besides age, the apo(a) phenotype is the best predictor of carotid atherosclerosis in ESRD patients and may be used for assessment of general atherosclerosis risk in this patient group.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8068600     DOI: 10.1161/01.atv.14.9.1405

Source DB:  PubMed          Journal:  Arterioscler Thromb        ISSN: 1049-8834


  5 in total

1.  Enhanced macrophage uptake of lipoprotein(a) after Ca2+-induced aggregate-formation.

Authors:  S Tanaka; A Yashiro; H Tasaki; Y Nakashima
Journal:  Lipids       Date:  1998-04       Impact factor: 1.880

2.  Relation of Apo(a) size to carotid atherosclerosis in an elderly multiethnic population.

Authors:  Furcy Paultre; Catherine H Tuck; Bernadette Boden-Albala; Douglas E Kargman; Elizabeth Todd; Jeffrey Jones; Myunghee C Paik; Ralph L Sacco; Lars Berglund
Journal:  Arterioscler Thromb Vasc Biol       Date:  2002-01       Impact factor: 8.311

3.  High levels of inflammatory biomarkers are associated with increased allele-specific apolipoprotein(a) levels in African-Americans.

Authors:  Erdembileg Anuurad; Jill Rubin; Alan Chiem; Russell P Tracy; Thomas A Pearson; Lars Berglund
Journal:  J Clin Endocrinol Metab       Date:  2008-02-05       Impact factor: 5.958

Review 4.  Lipoprotein(a) in nephrological patients.

Authors:  Bernd Hohenstein
Journal:  Clin Res Cardiol Suppl       Date:  2017-03

Review 5.  The role of lipoprotein (a) in chronic kidney disease.

Authors:  Jemma C Hopewell; Richard Haynes; Colin Baigent
Journal:  J Lipid Res       Date:  2018-01-29       Impact factor: 5.922

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.